Isomorphic Labs to Receive $45 Million in Upfront Payment with Potential Total Deal Value up to $1.7 Billion

Isomorphic Labs将获得4500万美元的预付款，潜在交易总价值高达17亿美元

LONDON, Jan. 7, 2024 /PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today announced that it has entered into a strategic research collaboration with Eli Lilly and Company. This marks Isomorphic Labs' first pharmaceutical partnership..

伦敦，2024年1月7日/PRNewswire/--数字生物学公司Isomorphic Labs今天宣布，它已与礼来公司（Eli Lilly and company）进行战略研究合作，该公司的使命是利用人工智能的力量重新定义药物发现。这标志着Isomorphic Labs的首次药物合作。。

Under the terms of the agreement, Isomorphic Labs will partner with Lilly to discover small molecule therapeutics against multiple targets and will receive an upfront cash payment of $45 million. Isomorphic Labs is eligible to receive up to $1.7 billion in performance-based milestone payments, excluding the upfront payment and any subsequent tiered royalties of up to low double digits on net sales..

根据协议条款，Isomorphic Labs将与礼来合作，发现针对多个目标的小分子疗法，并将获得4500万美元的预付现金。Isomorphic Labs有资格获得高达17亿美元的基于性能的里程碑付款，不包括预付款和任何后续的分层版税，净销售额不超过两位数。。

'We're thrilled to embark on this partnership and apply our proprietary technology platform, the next generation of AlphaFold, and access to massive computing power to Lilly's development programs,' said Demis Hassabis, CEO and founder of Isomorphic Labs. 'The focus we share on advancing groundbreaking drug design approaches and appreciation of state-of-the-art science makes this partnership particularly compelling.'.

Isomorphic Labs首席执行官兼创始人黛米斯·哈萨比斯（DemisHassabis）说，我们很高兴开始这一合作关系，并将我们的专有技术平台AlphaFold的下一代应用于礼来的开发项目，并获得巨大的计算能力我们共同致力于推进开创性的药物设计方法和对最先进科学的欣赏，这使得这种合作关系特别引人注目。”。

Isomorphic Labs operates autonomously within Alphabet, with its own dedicated resources and exclusive focus on the application of AI to drug discovery. The company is reimagining the entire drug discovery process from first principles with an AI-first approach, working to build powerful new predictive and generative models of biological phenomena to anticipate how drugs will perform and design novel molecules..

Isomorphic Labs在Alphabet内自主运营，拥有自己的专用资源，专注于AI在药物发现中的应用。该公司正在用人工智能优先的方法从第一原理重新想象整个药物发现过程，致力于建立强大的新的生物现象预测和生成模型，以预测药物的表现和设计新分子。。

Building on the success of AlphaFold and working in collaboration with Google DeepMind, Isomorphic Labs has made remarkable progress in developing the Next Generation of AlphaFold. This new iteration of AlphaFold expands beyond proteins to include small molecules and nucleic acids. Through deep integration of this next generation AlphaFold with other breakthrough AI models developed at Isomorphic Labs, the company is able to better understand the underlying biological mechanisms of drug targets, and rationally design novel therapeutics..

在AlphaFold成功的基础上，与Google DeepMind合作，Isomorphic Labs在开发下一代AlphaFold方面取得了显着进展。AlphaFold的新迭代扩展到蛋白质之外，包括小分子和核酸。通过将下一代AlphaFold与Isomorphic Labs开发的其他突破性AI模型进行深度集成，该公司能够更好地了解药物靶标的潜在生物学机制，并合理设计新型疗法。。

ABOUT ISOMORPHIC LABS

关于同构实验室

Isomorphic Labs is an autonomous subsidiary of Alphabet that was launched from Alphabet's DeepMind in 2021 to build on the success of AlphaFold, the company's groundbreaking work in protein folding. That work was heralded as the 'Breakthrough of the Year' by Science and 'Method of the Year' by Nature in 2021.

Isomorphic Labs是Alphabet的一个自主子公司，该公司于2021年从Alphabet的DeepMind成立，以AlphaFold的成功为基础，AlphaFold是该公司在蛋白质折叠方面的开创性工作。2021年，这项工作被《科学》和《自然》分别称为“年度突破”和“年度方法”。

Based in London and now with a second location in Lausanne, Switzerland, Isomorphic Labs was founded and is led by AI pioneer Demis Hassabis, who also co-founded and leads Google DeepMind. As pioneers in digital biology, the company's mission is to use AI to accelerate drug discovery and ultimately find cures for some of humanity's most devastating diseases.

Isomorphic Labs成立于伦敦，目前在瑞士洛桑拥有第二个办公地点，由人工智能先驱德米斯·哈萨比斯（DemisHassabis）领导，他也是谷歌DeepMind的联合创始人和领导者。作为数字生物学的先驱，该公司的使命是利用人工智能加速药物发现，并最终找到治疗人类某些最具毁灭性疾病的方法。

Using its AI-first approach to drug discovery and biology, the company's ambition is to advance a new era of medical breakthroughs. For more information, go to www.isomorphiclabs.com or follow us on LinkedIn and X..

该公司将其人工智能的第一方法用于药物发现和生物学，其目标是推进医学突破的新时代。有关更多信息，请访问www.isomorphiclabs.com或在LinkedIn和X上关注我们。。

SOURCE Isomorphic Labs

源同构实验室